Nicotinamide Sterop (Nicotinamide)

Nicotinamide serves as a precursor for NAD+, a vital co‑enzyme in redox reactions, DNA repair, and cellular signaling. After administration, it is converted to NAD+, enhancing metabolic pathways that rely on this molecule and helping maintain normal cellular function.

The appropriate dose of Nicotinamide Sterop is determined by the prescribing healthcare professional based on the patient’s condition, age, weight, and clinical response. Dosage regimens are individualized and should follow the prescriber’s instructions.

Safety data for Nicotinamide Sterop in pregnancy and lactation are limited. It should be used only if the potential benefit justifies any possible risk to the fetus or infant, and the decision should be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Nicotinamide Sterop provides a sterile injectable form of nicotinamide, allowing rapid systemic delivery, whereas oral niacin or nicotinamide tablets are absorbed more slowly and may cause flushing. Injectable nicotinamide avoids the flushing side effect and is useful when oral administration is not feasible.

Store Nicotinamide Sterop at ambient temperature, preferably below 25 °C. Keep the vials in their original packaging, protect them from moisture and direct light, and discard any product that appears discolored or contains particles.

Nicotinamide Sterop is administered by a qualified healthcare professional via intramuscular or intravenous injection. The route, injection site, and infusion rate are selected according to the patient’s clinical needs and the prescriber’s instructions.

Serious risks include anaphylactic reactions, severe hypotension, Stevens‑Johnson syndrome or toxic epidermal necrolysis, significant liver enzyme elevations, and hyperuricemia. Patients should be monitored for any signs of these reactions, and treatment should be stopped immediately if they occur.

Nicotinamide Sterop should be avoided in individuals with known hypersensitivity to nicotinamide or any excipients, in patients with severe hepatic or renal impairment without appropriate monitoring, and in those with a history of severe gout attacks unless benefits outweigh risks.